edoc

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study

Colleoni, Marco and Giobbie-Hurder, Anita and Regan, Meredith M. and Thürlimann, Beat and Mouridsen, Henning and Mauriac, Louis and Forbes, John F. and Paridaens, Robert and Láng, István and Smith, Ian and Chirgwin, Jacquie and Pienkowski, Tadeusz and Wardley, Andrew and Price, Karen N. and Gelber, Richard D. and Coates, Alan S. and Goldhirsch, Aron. (2011) Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. Journal of clinical oncology, Vol. 29, H. 9. pp. 1117-1124.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6005887

Downloads: Statistics Overview

Abstract

Among postmenopausal women with endocrine-responsive breast cancer, the aromatase inhibitor letrozole, when compared with tamoxifen, has been shown to significantly improve disease-free survival (DFS) and time to distant recurrence (TDR). We investigated whether letrozole monotherapy prolonged overall survival (OS) compared with tamoxifen monotherapy.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Onkologie
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Onkologie
UniBasel Contributors:Thürlimann, Beat
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:American Society of Clinical Oncology
ISSN:0732-183X
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:27 Mar 2014 13:13
Deposited On:27 Mar 2014 13:13

Repository Staff Only: item control page